13 Apr 06

Off-label anti-coagulants, diuretics, and calcium-channel blockers are often used to treat pulmonary arterial hypertension (PAH), with more targeted therapies like endothelin receptor antagonists, phosphodiesterase-5 inhibitors and prostacyclins also used extensively. While these treatments have all shown considerable efficacy, their shortcomings leave considerable unmet need in the PAH market.
Datamonitor

07 Apr 06

COPD is a disease that will grow in importance in the future and it will have a major impact on society, particular amongst those that smoke. At the moment, although new treatments are being developed for COPD the pharmaceutical market remains undeveloped. There will be a high demand for effective medicines and so COPD should be an area of interest for pharmaceutical companies who specialise in the respiratory therapeutic field.
Dr Faiz Kermani

07 Apr 06

Healthcare is receiving greater attention in Latin America than ever before and a number of countries in the region are in the midst of major reforms. The government policies that are being developed have important implications for pharmaceutical companies looking to expand in this emerging pharmaceutical region.
Dr Faiz Kermani

07 Apr 06

After the first failure of gene therapy, it's widely accepted that treatment leading to a cure for the 50,000 cystic fibrosis sufferers worldwide is an unachievable goal. The limited R&D efforts are instead directed towards disease modification and symptomatic treatments with ion channel modulators thought to hold some promise for the future.
Datamonitor

06 Apr 06

If you attend only one Drug Discovery World Congress this year, you don't want to miss this event!
James Prudhomme

06 Apr 06

Given its proximity to the huge US market, Canada is often overlooked with respect to its contribution to the pharmaceutical sector. Yet it is a well-established market in which all the major players are active and it has a vibrant R&D environment, both for traditional pharmaceutical companies and emerging biotech companies.
Dr Faiz Kermani

06 Apr 06

Japanese pharmaceutical companies have tended to avoid using mergers in their efforts to grow, but in recent times this attitude appears to have changed. Key mergers currently underway include Sankyo and Daiichi Pharmaceutical, Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical (who now operate as Astellas), and a tie-up between Dainippon Pharmaceutical and Sumitomo Pharmaceuticals.
Dr Faiz Kermani

06 Apr 06

China is a country that is rapidly modernising and as its economy grows its consumer base is changing. Many international biopharmaceutical companies have started to invest in China and believe that in the long-term the healthcare market offers huge commercial potential.
Dr Faiz Kermani

03 Apr 06

Corning Life Sciences today announced several new products coated with the Ultra-Low Attachment surface including the 25 and 75 cm2 flasks and CELLSTACK® Culture Chambers which are well-suited for many cell culture applications including stem cell, cancer, and immune system research, and enable customers to increase the scale of cell culture, improve yields, and reduce contamination risks
Corning Life Sciences

30 Mar 06

Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
Elias KAI

29 Mar 06

Deployable medicine involves the complete employment of military health professionals. The nature of the deployment can vary from conventional ‘warfighting’ campaigns to humanitarian relief operations. The methods for employing highly skilled military professionals within the area or operations and the level of care they provide are crucial to the success of the mission
marcus evans

29 Mar 06

The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
LeadDiscovery

28 Mar 06

Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
LeadDiscovery

27 Mar 06

The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.
ANDREW CLARK

23 Mar 06

e-Clinical Trials continue to be used more and more by the market leaders - There is no doubt though that the industry is soon to go fully electronic, so don't get behind the game... Our delegates have been demanding we run this event for the last 6 years! Here is what they have said about our past events: "...one of the best. I have learned a great deal about many of the important issues associated with e-Clinical Trials", Clinical Trial Manager/EDC Liason, Forest Labs Inc. "Informatio
Amir Sebahat

23 Mar 06

Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising. As more and more drugs are likely to come under regulatory and public scrutiny, the pharmaceutical industry will need to employ effective marketing and education strategies to ensure patient and physician confidence is retained and the impact of drug safety scares is minimized.
Datamonitor

22 Mar 06

According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.  The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.  Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
LeadDiscovery

21 Mar 06

If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
Rachel Davis

13 Mar 06

Insulin analogs are conquering the insulin market, inhaled insulins are the next generation, and oral insulins might bypass other delivery technologies
La Merie Business Intelligence

10 Mar 06

The Infectious Disease Society of America's new hit list of dangerous resistant bugs has drawn attention to the lack of new antibiotics under development. The society calls for the passing of legislation to encourage companies to re-enter the antibiotics arena. However, as Datamonitor's Lisette Oversteegen investigates, legislation alone is not enough to counter the growing threat of 'superbugs'.
Datamonitor

06 Mar 06

At least six fully human or humanized antibodies against insulin-like growth factor-1 receptor (IGF-1R) are in early clinical development or close to phase I
La Merie Business Intelligence

06 Mar 06

Back in 2000, I was really, really excited. Had I got a date with Kylie Minogue? No. Had West Ham won the Champions League? Not likely. I was excited because I thought I had discovered the best investment sector in the market -- life sciences.
Ed Bowsher

03 Mar 06

PharmiWeb recently asked Merck to provide some insight into what it was like to work as a sales rep for their company. Rather than just telling us what they thought we wanted to hear, they took the more open approach of asking their team for "real life" comments, and then gave us their rather impressive raw responses, with no additions or changes.
Vincent Lody

01 Mar 06

Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
LeadDiscovery

28 Feb 06

ICON’s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
Mike Wood

24 Feb 06

A glimpse of the broad-based, versatile business strategy that has enabled Abbott to combine dynamic growth with long-term stability.
Caroline Johnson

24 Feb 06

Abbott recently had the largest gain in reputation of any company in its industry when Fortune magazine ranked it number three in the magazine’s list of the most admired companies in the United States – Fortune’s highest ranking for Abbott since 1989. How was this achieved and what factors led up to it?
Caroline Johnson

24 Feb 06

In an increasingly complex world, with significant changes taking place on a social, commercial and economic basis almost weekly, corporate social responsibility is a priority for Abbott as it engages its stakeholders, advances its core objectives and exercises its influence – making productive contribution to the societies and communities it operates in.
Caroline Johnson

23 Feb 06

In their study due to be published in the March edition of Bioorg Med Chem Lett, Hoffmann and colleagues from Roche describe the design of two promising NK1 receptor antagonists, netupitant and befetupitant.
LeadDiscovery

21 Feb 06

Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to companies with an interest in biologic approach to oncology. The aptamers also forms the basis of a HTS assay that should help identify small molecule therapeutics for the treatment of hematological cancers
LeadDiscovery